Unaltered Angiogenesis-Regulating Activities of Platelets in Mild Type 2 Diabetes Mellitus despite a Marked Platelet Hyperreactivity.
Type 2 diabetes mellitus (T2DM) is associated with platelet dysfunction and impaired angiogenesis. Aim of the study is to investigate if platelet dysfunction might hamper platelet angiogenic activities in T2DM patients. Sixteen T2DM patients and gender/age-matched non-diabetic controls were studied. Flow cytometry and endothelial colony forming cell (ECFC) tube formation on matrigel were used to assess platelet reactivity and angiogenic activity, respectively. Thrombin receptor PAR1-activating peptide (PAR1-AP) induced higher platelet P-selectin expression, and evoked more rapid and intense platelet annexin V binding in T2DM patients, seen as a more rapid increase of annexin V+ platelets (24.3±6.4% vs 12.6±3.8% in control at 2 min) and a higher elevation (30.9±5.1% vs 24.3±3.0% at 8 min). However, PAR1-AP and PAR4-AP induced similar releases of angiogenic regulators from platelets, and both stimuli evoked platelet release of platelet angiogenic regulators to similar extents in T2DM and control subjects. Thus, PAR1-stimulated platelet releasate (PAR1-PR) and PAR4-PR similarly enhanced capillary-like network/tube formation of ECFCs, and the enhancements did not differ between T2DM and control subjects. Direct supplementation of platelets to ECFCs at the ratio of 1:200 enhanced ECFC tube formation even more markedly, leading to approximately 100% increases of the total branch points of ECFC tube formation, for which the enhancements were also similar between patients and controls. In conclusion, platelets from T2DM subjects are hyperreactive. Platelet activation induced by high doses of PAR1-AP, however, results in similar releases of angiogenic regulators in mild T2DM and control subjects. Platelets from T2DM and control subjects also demonstrate similar enhancements on ECFC angiogenic activities.
Karolinska Institutet, Department of Medicine-Solna, Clinical Pharmacology, Karolinska University Hospital-Solna, 171 76, Stockholm, Sweden.
Xinyan
X
Miao
Karolinska Institutet, Department of Medicine-Solna, Clinical Pharmacology, Karolinska University Hospital-Solna, 171 76, Stockholm, Sweden.
Wei
W
Zhang
Karolinska Institutet, Department of Medicine-Solna, Clinical Pharmacology, Karolinska University Hospital-Solna, 171 76, Stockholm, Sweden.
Zhangsen
Z
Huang
Karolinska Institutet, Department of Medicine-Solna, Clinical Pharmacology, Karolinska University Hospital-Solna, 171 76, Stockholm, Sweden.
Nailin
http://orcid.org/0000-0002-3848-7251
N
Li
D015415:Biomarkers; D001792:Blood Platelets / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D015539:Platelet Activation; D018179:Receptors, Thrombin / Q000378:metabolism
D015415:Biomarkers; D018179:Receptors, Thrombin